Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Inventory (2023 - 2026)

Beta Bionics' Inventory history spans 4 years, with the latest figure at $23.7 million for Q1 2026.

  • On a quarterly basis, Inventory rose 50.84% to $23.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $23.7 million, a 50.84% increase, with the full-year FY2025 number at $21.7 million, up 63.08% from a year prior.
  • Inventory hit $23.7 million in Q1 2026 for Beta Bionics, up from $21.7 million in the prior quarter.
  • Over the last five years, Inventory for BBNX hit a ceiling of $23.7 million in Q1 2026 and a floor of $1.2 million in Q4 2023.
  • Historically, Inventory has averaged $16.2 million across 4 years, with a median of $17.3 million in 2025.
  • Biggest five-year swings in Inventory: skyrocketed 969.88% in 2024 and later surged 50.84% in 2026.
  • Tracing BBNX's Inventory over 4 years: stood at $1.2 million in 2023, then skyrocketed by 969.88% to $13.3 million in 2024, then soared by 63.08% to $21.7 million in 2025, then rose by 9.23% to $23.7 million in 2026.
  • Business Quant data shows Inventory for BBNX at $23.7 million in Q1 2026, $21.7 million in Q4 2025, and $20.4 million in Q3 2025.